1 / 11

11th Annual CTOS Meeting November 19–21, 2005

Mutated p53 correlates with extreme sensitivity to Yondelis  in low passaged cell lines explanted from chemonaive sarcoma patients. V. Moneo, B.G. Serrelde, M. Taron, J. Fominaya, J.F. Martinez-Leal, C. Blanco-Aparicio, L. Romero, M. Sánchez-Beato,J.C Cigudosa,

zelenia-phelps
Download Presentation

11th Annual CTOS Meeting November 19–21, 2005

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Mutated p53 correlates with extreme sensitivity to Yondelis in low passaged cell lines explanted from chemonaive sarcoma patients V. Moneo, B.G. Serrelde, M. Taron, J. Fominaya, J.F. Martinez-Leal, C. Blanco-Aparicio, L. Romero, M. Sánchez-Beato,J.C Cigudosa, J.C Tercero, M.A. Piris, J. Jimeno, A. Carnero CNIO Dpt. Of Molecular Biology, Madrid, Spain PharmaMar R&D, Colmenar Viejo, Madrid, Spain 11th Annual CTOS Meeting November 19–21, 2005

  2. Proposed mechanisms of action ofET-743 ET-743 (Yondelis) Ecteinascidia turbinata • Binding to the minor groove of DNA • Interaction with transcription factors and DNA binding proteins • Interference DNA repair pathways

  3. Objective Remissions and Tumor Control in patients with Progressive STS Treated with Yondelis PFS-6 CR+PR

  4. Yondelis Long Lasting Objective Response in a patient with Anthracycline Resistant High Grade Liposarcoma Courtesy of Dr G Demetri

  5. In vitro Cytotoxicity assays • MTT assay 96h • Clonogenic assay • Q-RT-PCR: mRNA expression • Western: protein expression • full gene p-53 sequencing Generation and molecular characterization of the low passage sarcoma cell lines

  6. Sarcoma primary cell line panel ET-743 vs Doxorubicin IC50

  7. SR2103/1A SR2103/1B R R S S S S S S S S S S R R S S S S R R S S R R SR2103/A SR2103/B SR0312 SR0406 LS0904 RS0306 RS0306 CA1010 SR2205 SR0312 SR0406 SR2410 SR2910 CA1010 SR2205 LS0904 SR2410 SR2910 SW 872 SW 872 A673 A673 Apaf-1 p 21cip1 p73 p 27kip1 PTEN p16INK4a p15INK4b p85 p14ARF E-cad MSH-2 b-cat APC MLH-1 b-actin b-actin Molecular characterization sarcoma cell lines mRNA expression

  8. SR2103/A SR2103/B RS0306 CA1010 SR2205 SR2410 SR2910 SW 872 SR0312 SR0406 LS0904 A673 MUT p53 R S S S S S R S S R S R MDM2 cdk4 Cyc D1 S p27 Tubulina Molecular characterization sarcoma cell lines Protein expression A. Carnero, AARC-04

  9. Sarcoma primary cell line panel p53 mutational status Mut. p53

  10. 120 P53+/+ 110 100 90 80 70 60 50 40 30 -2 -1 0 1 2 3 4 5 6 ET-743 (log pM) P53-/- IC50 (nM) HCT116 Expt 1 Expt 2 Expt 3 P53 wt 16.63 11.30 15.89 P53 null 4.92 3.22 5.05 Impact of p53 knock-out on cytotoxicity of Yondelis

  11. Conclusions • This primary sarcoma panel has established a set of cell lines with differential extreme sensitivity to Yondelis (IC50 < 1nM).Such concentration range is reacheable in plasma well below the recommended dose. • Yondelis lacks complete cross-resistance with doxorubicin. • The extreme sensitivity to Yondelis is correlated with mp53 genotype(p<0.01). • This data might be of clinical relevance since it can provide a tool to characterize the response/resistance to Yondelis in patients. • Correlative studies in tumor samples from sarcoma patients treated with Yondelis are ongoing.

More Related